Wednesday, July 8, 2026

Patent intelligence · US

US 12370188

Formulations of dazucorilant, a glucocorticoid receptor modulator

granted A61KA61K31/4745A61K47/10A61K47/22
Status granted
Linked drugs 2
Pipeline programs 6
Years to expiry 19
Applicant portfolio 120
Patent details — US 12370188
Jurisdiction
US
Status
granted
Grant date
Jul 29, 2025
Expiration
Jul 24, 2045
Claims
10
CPC classes
A61K, A61K31/4745, A61K47/10, A61K47/22
View on Google Patents ↗

Quick answer

US 12370188 (Formulations of dazucorilant, a glucocorticoid receptor modulator) is held by Corcept Therapeutics Incorporated. Status: granted. Granted Jul 29, 2025. Expires Jul 24, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
10
CPC classes
A61K, A61K31/4745, A61K47/10, A61K47/22, A61K9/4825, A61K9/4858

More from Corcept Therapeutics Incorporated

Related pharmaceutical patents in our USPTO index.

  1. US 12370175

    Glucocorticoid receptor modulators to treat pancreatic cancer

    Corcept Therapeutics Incorporated · Expires Jul 24, 2045

    granted
  2. US 12336985

    Methods for shrinking pituitary tumors

    Corcept Therapeutics Incorporated · Expires Jun 19, 2045

    granted
  3. US 12290551

    Methods for imaging and treatment of somatostatin-receptor positive tumors

    Corcept Therapeutics Incorporated · Expires May 1, 2045

    granted
  4. US 12285425

    Glucocorticoid receptor modulators to treat cervical cancer

    Corcept Therapeutics Incorporated · Expires Apr 24, 2045

    granted
  5. US 12263169

    Methods of treating neuroepithelial tumors using selective glucocorticoid receptor modulators

    Corcept Therapeutics Incorporated · Expires Mar 27, 2045

    granted
  6. US 12226417

    Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists

    Corcept Therapeutics Incorporated · Expires Feb 13, 2045

    granted
  7. US 12226412

    Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators

    Corcept Therapeutics Incorporated · Expires Feb 13, 2045

    granted

Frequently asked questions

What is US patent 12370188?

US 12370188 (Formulations of dazucorilant, a glucocorticoid receptor modulator) is held by Corcept Therapeutics Incorporated. Status: granted. Granted Jul 29, 2025. Expires Jul 24, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 12370188?

Corcept Therapeutics Incorporated is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 120 pharmaceutical patents for this assignee.

When does US 12370188 expire?

Our index shows an expiration date of Jul 24, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.